Clinical Insights & Research — 2026
The Journal.
Evidence-based peptide therapy insights, regulatory
updates, obesity and metabolism education, and practical
clinical guidance for modern providers.
Six Peptides Received Favorable Advisory Recommendations: What Every Clinician Needs To Know After The FDA’s July 2026 Review
by: Lauren SupraPublished on: 09/08/2026For healthcare professionals who follow peptide therapy, this meeting represented much more than a routine regulatory discussion
Before You Compare The Dose, Understand The Route: Why Oral And Injectable Peptides Are Not Interchangeable
by: Lauren SupraPublished on: 29/06/2026One of the biggest misconceptions in peptide therapy is that oral and injectable peptides are interchangeable. Many clinicians look at a dose and assume the body receives that entire amount regardless of how the peptide is administered.
The FDA Is Reviewing Key Peptides For Compounding Ahead Of July 2026
by: Lauren SupraPublished on: 15/06/2026Peptide therapy is one of the most exciting areas in modern medicine right now. The clinicians who choose to understand it deeply will be the ones helping shape where this field goes next.
Retatrutide: The Triple Agonist Changing How Clinicians Think About Obesity Medicine
by: Lauren SupraPublished on: 21/05/2026Retatrutide is still investigational. Long-term safety data is still needed, along with more research, and more clinical experience. However, medicine is entering a completely different era of metabolic treatment.
Join the mailing list and receive 15% off your first course enrollment
Get course updates, peptide education insights, and a special first-time enrollment offer
Dedicated to the advancement of clinical excellence through evidence-based peptide therapy education.
Quick Links
Our Commitment
Advancing clinical excellence through education you can trust and apply.
© 2026 Advera Care - All Rights Reserved.
Designed by Joamar Derije [Autobookr.io]
